{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:24:54Z","timestamp":1772166294076,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["BAA-N01CM51007-51"],"award-info":[{"award-number":["BAA-N01CM51007-51"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To identify a safe carbon ion radiotherapy (CIRT) regimen for patients with locally advanced pancreatic cancer (LAPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We generated treatment plans for 13 consecutive, unselected patients who were treated for LAPC with CIRT at our center using three dose and fractionation schedules: 4.6 GyRBE\u2009\u00d7\u200912, 4.0 GyRBE\u2009\u00d7\u200914, and 3.0 GyRBE\u2009\u00d7\u200917. We tested the ability to meet published dose constraints for the duodenum, stomach, and small bowel as a function of dose schedule and distance between the tumor and organs at risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Using 4.6 GyRBE\u2009\u00d7\u200912 and 4.0 GyRBE\u2009\u00d7\u200914, critical (high-dose) constraints could only reliably be achieved when target volumes were not immediately adjacent to organs at risk. Critical constraints could be met in all cases using 3.0 GyRBE\u2009\u00d7\u200917. Low-dose constraints could not uniformly be achieved using any dose schedule.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While selected patients with LAPC may be treated safely with a CIRT regimen of 4.6 GyRBE\u2009\u00d7\u200912, our dosimetric analyses indicate that a more conservative schedule of 3.0 GyRBE\u2009\u00d7\u200917 may be required to safely treat a broader population of LAPC patients, including those with large tumors and tumors that approach gastrointestinal organs at risk. The result of this work was used to guide an ongoing clinical trial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-020-01515-5","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T05:03:25Z","timestamp":1588827805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluating dosimetric constraints for carbon ion radiotherapy in the treatment of locally advanced pancreatic cancer"],"prefix":"10.1186","volume":"15","author":[{"given":"Lien-Chun","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Liang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin","family":"Ohri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiade J.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhur","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandan","family":"Guha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"key":"1515_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"1515_CR2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1245\/s10434-009-0762-4","volume":"17","author":"AG Morganti","year":"2010","unstructured":"Morganti AG, Massaccesi M, La Torre G, Caravatta L, Piscopo A, Tambaro R, et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol. 2010;17:194\u2013205.","journal-title":"Ann Surg Oncol"},{"key":"1515_CR3","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","volume":"315","author":"P Hammel","year":"2016","unstructured":"Hammel P, Huguet F, van Laethem J-L, Goldstein D, Glimelius B, Artru P, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. Jama. 2016;315:1844\u201353.","journal-title":"Jama."},{"key":"1515_CR4","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","volume":"19","author":"B Chauffert","year":"2008","unstructured":"Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouch\u00e9 O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000\u201301 FFCD\/SFRO study. Ann Oncol. 2008;19:1592\u20139.","journal-title":"Ann Oncol"},{"key":"1515_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1200\/JCO.2006.07.5663","volume":"25","author":"F Huguet","year":"2007","unstructured":"Huguet F, Andr\u00e9 T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25:326\u201331.","journal-title":"J Clin Oncol"},{"key":"1515_CR6","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","volume":"29","author":"PJ Loehrer","year":"2011","unstructured":"Loehrer PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an eastern cooperative oncology group trial. J Clin Oncol. 2011;29:4105\u201312.","journal-title":"J Clin Oncol"},{"key":"1515_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1470-2045(13)70021-4","volume":"14","author":"S Mukherjee","year":"2013","unstructured":"Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14:317\u201326.","journal-title":"Lancet Oncol"},{"key":"1515_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1200\/JCO.1985.3.3.373","volume":"3","author":"D Klaassen","year":"1985","unstructured":"Klaassen D, MacIntyre J, Catton G, Engstrom P, Moertel C. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an eastern cooperative oncology group study. J Clin Oncol. 1985;3:373\u20138.","journal-title":"J Clin Oncol"},{"key":"1515_CR9","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/jnci\/80.10.751","volume":"80","author":"Group GTS","year":"1988","unstructured":"Group GTS. Treatment of locally Unresectable carcinoma of the pancreas: comparison of combined-modality therapy (Chemotheraphy plus radiotherapy) to Chemotheraphy Alone1. J Natl Cancer Inst. 1988;80:751\u20135.","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"1515_CR10","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1200\/JCO.2014.59.7930","volume":"33","author":"GM Heestand","year":"2015","unstructured":"Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol. 2015;33(16):1770\u20138.","journal-title":"J Clin Oncol"},{"key":"1515_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/01.coc.0000046037.75545.AD","volume":"27","author":"Y Matsui","year":"2005","unstructured":"Matsui Y, Asano T, Kenmochi T, Iwakawa M, Imai T, Ochiai T. Effects of carbon-ion beams on human pancreatic cancer cell lines that differ in genetic status. Am J Clin Oncol. 2005;27:24\u20138.","journal-title":"Am J Clin Oncol"},{"key":"1515_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.radonc.2012.08.009","volume":"105","author":"K Oonishi","year":"2012","unstructured":"Oonishi K, Cui X, Hirakawa H, Fujimori A, Kamijo T, Yamada S, et al. Different effects of carbon ion beams and X-rays on clonogenic survival and DNA repair in human pancreatic cancer stem-like cells. Radiother Oncol. 2012;105:258\u201365.","journal-title":"Radiother Oncol"},{"key":"1515_CR13","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0360-3016(00)00803-8","volume":"48","author":"AC Koong","year":"2000","unstructured":"Koong AC, Mehta VK, Le QT, Fisher GA, Terris DJ, Brown JM, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys. 2000;48:919\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1515_CR14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ijrobp.2015.12.362","volume":"95","author":"M Shinoto","year":"2016","unstructured":"Shinoto M, Yamada S, Terashima K, Yasuda S, Shioyama Y, Honda H, et al. Carbon ion radiation therapy with concurrent gemcitabine for patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2016;95:498\u2013504.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1515_CR15","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1088\/0031-9155\/51\/8\/001","volume":"51","author":"M Kr\u00e4mer","year":"2006","unstructured":"Kr\u00e4mer M, Scholz M. Rapid calculation of biological effects in ion radiotherapy. Phys Med Biol. 2006;51:1959.","journal-title":"Phys Med Biol"},{"key":"1515_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s004110050055","volume":"36","author":"M Scholz","year":"1997","unstructured":"Scholz M, Kellerer A, Kraft-Weyrather W, Kraft G. Computation of cell survival in heavy ion beams for therapy. Radiat Environ Biophys. 1997;36:59\u201366.","journal-title":"Radiat Environ Biophys"},{"key":"1515_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.radonc.2016.04.040","volume":"0120","author":"M Shinoto","year":"2016","unstructured":"Shinoto M, Shioyama Y, Matsunobu A, Okamoto K, Suefuji H, Toyama S, et al. Dosimetric analysis of upper gastrointestinal ulcer after carbon-ion radiotherapy for pancreatic cancer. Radiother Oncol. 2016;0120:140\u20134.","journal-title":"Radiother Oncol"},{"key":"1515_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0360-3016(98)00544-6","volume":"44","author":"T Kanai","year":"1999","unstructured":"Kanai T, Endo M, Minohara S, Miyahara N, Koyama-Ito H, Tomura H, et al. Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J Radiat Oncol Biol Phys. 1999;44:201\u201310.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1515_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1088\/0031-9155\/53\/1\/003","volume":"53","author":"Y Kase","year":"2007","unstructured":"Kase Y, Kanai T, Matsufuji N, Furusawa Y, Els\u00e4sser T, Scholz M. Biophysical calculation of cell survival probabilities using amorphous track structure models for heavy-ion irradiation. Phys Med Biol. 2007;53:37.","journal-title":"Phys Med Biol"},{"issue":"5","key":"1515_CR20","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.ijrobp.2018.07.2023","volume":"102","author":"AJ Ghia","year":"2018","unstructured":"Ghia AJ, Guha-Thakurta N, Hess K, Yang JN, Settle SH, Sharpe HJ, et al. Phase 1 study of spinal cord constraint relaxation with single session spine stereotactic radiosurgery in the primary management of patients with inoperable, previously unirradiated metastatic epidural spinal cord compression. Int J Radiat Oncol Biol Phys. 2018;102(5):1481\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1515_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"JD Bradley","year":"2015","unstructured":"Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187\u201399.","journal-title":"Lancet Oncol"},{"key":"1515_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fonc.2015.00145","volume":"5","author":"M Durante","year":"2015","unstructured":"Durante M, Tommasino F, Yamada S. Modeling combined chemotherapy and particle therapy for locally advanced pancreatic cancer. Front Oncol. 2015;5:145.","journal-title":"Front Oncol"},{"key":"1515_CR23","doi-asserted-by":"publisher","first-page":"7543","DOI":"10.1088\/0031-9155\/57\/22\/7543","volume":"57","author":"P Fossati","year":"2012","unstructured":"Fossati P, Molinelli S, Matsufuji N, Ciocca M, Mirandola A, Mairani A, et al. Dose prescription in carbon ion radiotherapy: a planning study to compare NIRS and LEM approaches with a clinically-oriented strategy. Phys Med Biol. 2012;57:7543.","journal-title":"Phys Med Biol"},{"key":"1515_CR24","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1200\/JCO.2005.04.3844","volume":"24","author":"D Normolle","year":"2006","unstructured":"Normolle D, Lawrence T. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method. J Clin Oncol. 2006;24:4426\u201333.","journal-title":"J Clin Oncol"},{"key":"1515_CR25","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.1200\/JCO.2007.12.0592","volume":"25","author":"SP Desai","year":"2007","unstructured":"Desai SP, Ben-Josef E, Normolle DP, Francis IR, Greenson JK, Simeone DM, et al. Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. J Clin Oncol. 2007;25:4587\u201392.","journal-title":"J Clin Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-01515-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-020-01515-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-01515-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T19:27:01Z","timestamp":1620329221000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-020-01515-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1515"],"URL":"https:\/\/doi.org\/10.1186\/s13014-020-01515-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.23301\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.23301\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.23301\/v1","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,7]]},"assertion":[{"value":"7 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The approval by Shanghai Proton and Heavy Ion Center IRB was obtained for this study.Approval #: 171023EXP-01.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}